Tags : Metastatic Triple-Negative Breast Cancer

Immunomedics Reports the US FDA’s Acceptance of BLA for Sacituzumab

Shots: The US FDA has accepted resubmission of BLA, seeking accelerated approval of sacituzumab govitecan to treat patients with mTNBC, prior treated with at least two therapies for metastatic disease, as a complete class 2 response The company is closely working with the US FDA to facilitate its review on BLA, which allow the company […]Read More